Last updated 2026-06-18
Total raised
—
Stage
Mature
Founded
2011
Headcount
1
HQ
Ness Ziona, Israel
Sector
—
About
InjecTec has developed MultiTox, an innovative cradle for multi-use injections. The MultiTox cradle and syringe address the need for accuracy, precise placement, and exact dosage during botulinum toxin injections. The cradle accepts a standard sterile syringe and moves the plunger in a stepped manner to facilitate precise, multiple dosages of botulinum toxin. The patent-pending MultiTox cradle is positioned in the hand the same way a syringe is held. Pressing with the palm or the thumb activates the syringe. InjecTec is part of the BDR Group.
Q&A
- What is InjecTec's primary product?
- InjecTec has developed MultiTox, an innovative cradle for multi-use injections designed to provide accuracy, precise placement, and exact dosage during botulinum toxin injections.
- When was InjecTec founded?
- InjecTec was founded in January 2011.
- What is the current status of InjecTec?
- InjecTec is currently inactive, a status it reached in March 2017.
- Where is InjecTec headquartered?
- InjecTec is headquartered in Ness Ziona, Center District, Israel.
- Who is the founder and CEO of InjecTec?
- Gershon Goldenberg is the Founder and CEO of InjecTec.
- What industry sectors does InjecTec operate in?
- InjecTec operates in the Health Tech & Life Sciences, Medical Devices, and Aesthetic Devices sectors.
- What is InjecTec's relationship with the BDR Group?
- InjecTec is part of the BDR Group.
Team · 1
Sectors & technology
Sub-sectors
Health Tech & Life SciencesMedical DevicesAesthetic Devices
Target customers
Healthcare & Life SciencesHealthcareProvidersLife SciencesCosmetics
Business model
B2B
Highlights
Verified
Tags
doctorsmedical-devicescosmeticspatent-pendingmedical-equipmentclinics
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| linkedin.com/company/3047547 |
Identifiers & details
| Founded | 2011-1 |
|---|---|
| Employees (exact) | 1 |
| Status reason | Non Active, Mar 2017 |